Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimipramine, Atezolizumab and Bevacizumab in Recurrent Glioblastoma
NCT07263438Phase 2Recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trimipramine, atezolizumab in glioblastoma (GBM), sponsored by Lausanne University Hospital. Started Nov 2025; status: recruiting.
02
Drugs
trimipramineatezolizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07263438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07263438.